Bellerophon Therapeutics is a
clinical-stage biotherapeutics company.

We are focused on developing innovative therapies in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.

More About Us

Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).

More About INOpulse

Our goal is to become a leader in developing and commercializing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

More About Pipeline

Bellerophon Therapeutics Inc. News Release

A Collection of Bellerophon Therapeutics Inc. News Release

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
05/15/2023 08:50 PM

Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J. , May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
05/11/2023 12:30 PM

Pivotal top-line data readout expected in mid-2023 WARREN, N.J. , May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced

Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results
03/31/2023 12:30 PM

Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023 Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater China Strengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused

Bellerophon Therapeutics Announces $5 Million Registered Direct Offering
03/06/2023 01:30 PM

WARREN, N.J. , March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a subscription agreement

Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease
02/09/2023 01:30 PM

China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint WARREN, N.J. , Feb. 09, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing


More News

 


Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).

More About Inopulse


Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

More About Our Pipeline

Bellerophon Therapeutics Inc. News Release

A Collection of Bellerophon Therapeutics Inc. News Release

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
05/15/2023 08:50 PM

Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J. , May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
05/11/2023 12:30 PM

Pivotal top-line data readout expected in mid-2023 WARREN, N.J. , May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced

Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results
03/31/2023 12:30 PM

Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023 Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater China Strengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused

Bellerophon Therapeutics Announces $5 Million Registered Direct Offering
03/06/2023 01:30 PM

WARREN, N.J. , March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a subscription agreement

Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease
02/09/2023 01:30 PM

China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint WARREN, N.J. , Feb. 09, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing


More News